Inspire Medical Systems’s (NYSE:INSP) Q4: Beats On Revenue
Medical technology company Inspire Medical Systems (NYSE:INSP) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24.5% year on year to $239.7 million. The company expects the full year’s revenue to be around $947.
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 10, 2025 Inspire Medical Systems, Inc. beats earnings expectations. Reported EPS is $1.15, expectations were $0.74. Operator: Good afternoon. My name is Dilem [ph] and I’ll be your conference operator today.
Stifel Nicolaus Sticks to Its Hold Rating for Inspire Medical Systems (INSP)
In a report released today, Jonathan Block from Stifel Nicolaus maintained a Hold rating on Inspire Medical Systems (INSP – Research Report),
A Look At The Fair Value Of Inspire Medical Systems, Inc. (NYSE:INSP)
Key Insights The projected fair value for Inspire Medical Systems is US$209 based on 2 Stage Free Cash Flow to
Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know. Inspire Medical Systems beat analysts’ revenue expectations by 2.
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook
MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024.
Truist cuts Inspire Medical stock target to $235, retains buy rating
Truist Securities adjusted its price target for Inspire Medical Systems (NYSE:INSP) stock, lowering it from $250.00 to $235.00 while maintaining a Buy rating. The adjustment follows the company's fourth-quarter earnings per share (EPS) beat and a guidance for 2025 that surpassed consensus estimates.
Inspire Medical Systems targets $940M-$955M revenue in 2025 with Inspire V launch
Q4 2024 Management View CEO Tim Herbert highlighted milestones in 2024, including surpassing 90,000 patients treated with Inspire therapy, FDA approval of the Inspire V neurostimulator, and achieving full-body MRI compatibility in the European Union.
Truist Financial Sticks to Their Buy Rating for Inspire Medical Systems (INSP)
In a report released today, Richard Newitter from Truist Financial maintained a Buy rating on Inspire Medical Systems (INSP – Research Report).
MassDevice23h
Inspire Medical faces DOJ investigation
Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...
ETF Daily News17d
Inspire Medical Systems (NYSE:INSP) Given Overweight Rating at KeyCorp
Shares of NYSE INSP opened at $188.77 on Friday. The company has a 50 day moving average of $189.32 and a 200 day moving average of $186.43. Inspire Medical Systems has a twelve month low of $123. ...
Nasdaq18d
Deep Dive Into Inspire Medical Systems Stock: Analyst Perspectives (8 Ratings)
8 analysts have expressed a variety of opinions on Inspire Medical Systems (NYSE:INSP) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes ...
Investing6d
Inspire Medical Systems Inc (INSP)
Inspire Medical Systems (NYSE:INSP) reported Q2 EPS of ($0.53), $0.08 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $91.4 million versus the... Leerink Partners ...
Inspire Medical Systems, Inc. (NYSE:INSP) Stock Position Raised by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC lifted its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP – Free Report) by 37.3% during the fourth quarter, Holdings Channel reports. The firm owned 368 ...